Immunohistochemical features of CD133 expression: Association with resistance to chemoradiotherapy in rectal cancer

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 345-350

  Saigusa, Susumu ^a   Tanaka, Koji ^a   Toiyama, Yuji ^a   Yokoe, Takeshi ^a   Okugawa, Yoshinaga ^a   Kawamoto, Aya ^a   Yasuda, Hiromi ^a   Morimoto, Yuki ^a   Fujikawa, Hiroyuki ^a   Inoue, Yasuhiro ^a   Miki, Chikao ^a   Kusunoki, Masato ^a,b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Molec Oncol and Med Biotech Div   (Japan)

Author keywords

CD133; Chemoradiotherapy; Colorectal cancer; Immunohistochemistry

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; UFT; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MESSENGER RNA; PEPTIDE; PHARMACOLOGICAL BIOMARKER; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; CONTINUOUS INFUSION; CYTOPLASM; DOSE RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RECTUM CANCER; STAINING; TISSUE SECTION; TUMOR GROWTH; ADULT; AGED; BIOLOGICAL MODEL; CARCINOMA; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; HT 29 CELL LINE; METABOLISM; MIDDLE AGED; PROGNOSIS; RADIATION RESPONSE; RECTAL NEOPLASMS;

ADULT; AGED; ANTIGENS, CD; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDES; PROGNOSIS; RADIATION DOSAGE; RADIATION TOLERANCE; RECTAL NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77954350454     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000865     Document Type: Article

References (20)

1. O'Brien CA, Pollett A, Gallinger S, et al: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
2. Polyak K and Hahn WC: Roots and stems: stem cells in cancer. Nat Med 12: 296-300, 2006.
3. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
4. Vermeulen L, Sprick MR, Kemper K, et al: Cancer stem cells, old concepts, new insights. Cell Death Differ 15: 947-958, 2008.
5. Boman BM and Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26: 2828-2838, 2008.
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
7. Ieta K, Tanaka F, Haraguchi N, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 15: 638-648, 2008.
8. - metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120, 2008.
9. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
10. Rich JN: Cancer stem cells in radiation resistance. Cancer Res 67: 8980-8984, 2007.
11. Todaro M, Alea MP, Di Stefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402, 2007. (Pubitemid 47506537)
12. Saigusa S, Tanaka K, Toiyama Y, et al: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16: 3488-3498, 2009.
13. Yasuda H, Tanaka K, Saigusa S, et al: Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 22: 709-717, 2009.
14. Immervoll H, Hoem D, Sakariassen PO, et al: Expression of the 'stem cell marker' CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48, 2008.
15. Yoshikawa R, Kusunoki M, Yanagi H, et al: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001. (Pubitemid 32174421)
16. Japanese Society for Cancer of the Colon and Rectum. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum, and Anus. Tokyo, Kanehara & Co., 2006.
17. Choi D, Lee HW, Hur KY, et al: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15: 2258-2264, 2009.
18. Kojima M, Ishii G, Atsumi N, et al: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinico-pathological study. Cancer Sci 99: 1578-1583, 2008.
19. Horst D, Kriegl L, Engel J, et al: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
20. Jaksch M, Munera J, Bajpai R, et al: Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 68: 7882-7886, 2008.